Trials / Withdrawn
WithdrawnNCT01546896
Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This research aims to investigate the efficacy and safety of buspirone in treating generalized anxiety disorder with depressive symptoms and to evaluate its neuroprotective effects using magnetic resonance imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | buspirone+alprazolam | day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg |
| DRUG | alprazolam | 0.5mg/d |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2012-03-07
- Last updated
- 2015-05-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01546896. Inclusion in this directory is not an endorsement.